• About
  • Advertise
  • Careers
  • Write for us
  • Contact
  • Terms of service
No Result
View All Result
Thursday, April 22, 2021
THE MILLENNIAL SOURCE
  • World
  • US
  • Asia
  • Politics
  • Business
  • Profiles
  • Lifestyle
    • Food & Travel
    • Tech & Money
    • Health
    • Entertainment
  • Newsletter
TMS
No Result
View All Result
Home WORLD

Regeneron begins clinical trials for COVID-19 antibody treatment

byAnanta Agarwal
June 12, 2020
in WORLD
Reading Time: 3 mins read
Regeneron begin clinical trials for antibody treatment to treat COVID-19

Source: The Business Journals

Share on FacebookShare on TwitterShare on Linkedin



On Thursday, Regeneron Pharmaceuticals announced that it had commenced its first clinical trial of COVID-19 antibody cocktail treatments in the United States. If successful, the company hopes to make the treatment, officially known as REGN-COV2, available for COVID-19 patients by fall. 

In a press release, Regeneron President and Chief Scientific Officer Dr. George Yancopoulos wrote, “We have created a unique anti-viral antibody cocktail with the potential both to prevent and treat infection, and also to preempt viral ‘escape,’ a critical precaution in the midst of an ongoing global pandemic.

“Ultimately, the world needs multiple solutions, and the innovative biopharma industry is collectively working hard to help as many people as possible with a variety of complementary approaches.”

The clinical trials, which started Wednesday, will be conducted on four different study groups. Patients who are sick and hospitalized with COVID-19, those who are sick but not hospitalized, individuals who are high at risk to contract the disease but haven’t yet been infected and people who have come in contact with someone who has been tested COVID-19 positive.

“REGN-COV2 could have a major impact on public health by slowing spread of the virus and providing a needed treatment for those already sick – and could be available much sooner than a vaccine,” said Yancopoulos. 

“The antibody cocktail approach may also have long-term utility for elderly and immuno-compromised patients, who often do not respond well to vaccines.”

Antibodies are produced against viruses and bacteria when the body responds to infection. The antibodies defend a cell from infectious bacteria by neutralizing any effect it has biologically and can persist in an individual’s system for years and sometimes, decades. The antibodies can either be natural or artificial (e.g. vaccinations). To form an antibody cocktail, scientists at Regeneron have examined thousands of antibodies to pick out two which they hope will be most effective in treating COVID-19.

Eli Lilly and Co., Regeneron’s competitor, also started its clinical trials on June 1 for an antibody treatment which they have announced may be available by early September. 

However, Regeneron told CNBC on Thursday that its own treatment using a cocktail of two antibodies can prevent the virus from mutating, potentially offering a better solution. 

In response to Regeneron’s announcement, the Trump administration’s former Food and Drug Administration (FDA) Commissioner Scott Gottlieb, expressed concern over potential supply shortages of the treatment and called for government support in the manufacturing process.

“These antibody programs are on pace to potentially have a product for the Fall for emergency use,” he tweeted on Thursday.

“The challenge will be supply. The manufacturers will have limited doses unless the feds can help crash manufacturing capacity. This is where the government can play an important role.”

These antibody programs are on pace to potentially have a product for the Fall for emergency use. The challenge will be supply. The manufacturers will have limited doses unless the feds can help crash manufacturing capacity. This is where the government can play an important role https://t.co/Ol2AtSJMag

— Scott Gottlieb, MD (@ScottGottliebMD) June 11, 2020

Have a tip or story? Get in touch with our reporters at [email protected]

Related

Tags: North AmericaShort read
ShareTweetShare

Latest Posts

Here are the reactions to the guilty verdict in the Derek Chauvin case

Here are the reactions to the guilty verdict in the Derek Chauvin case

April 22, 2021
With the Coinbase IPO, what is the future of cryptocurrency?

With the Coinbase IPO, what is the future of cryptocurrency?

April 22, 2021
Here’s what business leaders think about Biden’s proposed tax plan

Here’s what business leaders think about Biden’s proposed tax plan

April 21, 2021

Derek Chauvin is found guilty of murdering George Floyd

April 21, 2021

Will Biden be able to pass lasting gun reform?

April 20, 2021

China is the epicenter of global tech production. What does that mean for the global economy?

April 20, 2021

China’s Belt and Road Initiative may have a competitor: The Blue Dot Network

April 20, 2021

Will China soon have more billionaires than the US?

April 20, 2021

Biden’s stance on Taiwan, Hong Kong and Xinjiang

April 19, 2021
  • About
  • Advertise
  • Careers
  • Write for us
  • Contact
  • Terms of service

© 2021 The Millennial Source Ltd.

No Result
View All Result
  • World
  • US
  • Asia
  • Politics
  • Business
  • Profiles
  • Lifestyle
    • Food & Travel
    • Tech & Money
    • Health
    • Entertainment
  • Newsletter

© 2021 The Millennial Source Ltd.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

The Millennial Source
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.